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Although cardiosphere-derived cells (CDCs) improve cardiac function and outcomes in patients 
with single ventricle physiology, little is known about their safety and therapeutic benefit in 
children with dilated cardiomyopathy (DCM). We aimed to determine the safety and efficacy of 
CDCs in a porcine model of DCM and translate the preclinical results into this patient 
population. A swine model of DCM using intracoronary injection of microspheres created 
cardiac dysfunction. Forty pigs were randomized as preclinical validation of the delivery 
method and CDC doses, and CDC-secreted exosomes (CDCex)-mediated cardiac repair was 
analyzed. A phase 1 safety cohort enrolled 5 pediatric patients with DCM and reduced ejection 
fraction to receive CDC infusion. The primary endpoint was to assess safety, and the secondary 
outcome measure was change in cardiac function. Improved cardiac function and reduced 
myocardial fibrosis were noted in animals treated with CDCs compared with placebo. These 
functional benefits were mediated via CDCex that were highly enriched with proangiogenic and 
cardioprotective microRNAs (miRNAs), whereas isolated CDCex did not recapitulate these 
reparative effects. One-year follow-up of safety lead-in stage was completed with favorable 
profile and preliminary efficacy outcomes. Increased CDCex-derived miR-146a-5p expression 
was associated with the reduction in myocardial fibrosis via suppression of proinflammatory 
cytokines and transcripts. Collectively, intracoronary CDC administration is safe and improves 
cardiac function through CDCex in a porcine model of DCM. The safety lead-in results in 
patients provide a translational framework for further studies of randomized trials and CDCex-





Dilated cardiomyopathy (DCM) in children is the most common form of pediatric 
cardiomyopathy and may manifest as diverse disorders with both acquired and genetic causes. 
Although the annual incidence of primary DCM in childhood is low, 5-year event-free survival 
from death or cardiac transplantation was estimated to be 50-60% (1). Because preclinical and 
clinical studies of heart failure therapies in patients with pediatric DCM have been limited by a 
lack of both suitable experimental models and sufficient statistical power to validate the 
endpoints due to the small sample sizes, few pharmacological treatments and 
nonpharmacological interventions have been developed to reduce mortality in children with 
advanced heart failure.  
The potential use of stem cells to attenuate the progressive reduction in ventricular function 
with congenital heart disease (CHD) has been a topic of considerable interest (2). Over recent 
years, the mobilization and direct delivery of various types of stem cells has expanded the 
possibilities for myocardial repair to treat children with CHD including DCM; however, few 
studies have been conducted using prospective, controlled trials (3, 4). Among the various types 
of stem cells applied in the pediatric population, intracoronary delivery of cardiosphere-derived 
cells (CDCs) has been shown to provide functional benefits over staged surgical palliations in 
children with single ventricle lesions (5-7). CDCs are intracardiac in origin and exhibit a 
heterogeneous population to form multicellular clusters composed of clonally-derived cells. Our 
initial results from the prospective phase 1 controlled study TICAP (Transcoronary Infusion of 
Cardiac Progenitor Cells in Single Ventricle Physiology) and randomized phase 2 controlled 




substantiated the safety profile as well as the therapeutic efficacy of CDC infusion in patients 
with structural heart diseases, and the subsequent long-term cohort study demonstrated a 
favorable impact on improvements in cardiac function and clinical outcomes (8). A recent 
randomized trial suggested a possible beneficial effect of intracoronary allogeneic CDCs in 
adolescents with neuromuscular disorders (9). Given the differential responses associated with 
CDC delivery observed in children compared with those in adults, outcomes might be 
dependent on the disease and age-related regenerative potentials of CDCs, mostly mediated 
through their secreted extracellular vesicles (10, 11). Whether patients with pediatric DCM 
benefit from CDC treatment remains elusive. 
In the current study, we established a porcine model with a dilated left ventricle (LV) and 
global systolic dysfunction by coronary microembolization to recapitulate the structural and 
functional phenotypes of DCM. This preclinical model was instrumental in the evaluation of 
procedural safety and therapeutic efficacy of nonocclusive transcoronary infusion of CDCs in 
pigs as part of a randomized dose-escalation study. Our results demonstrated that blockade of 
exosome secretion from CDCs decreased the benefits from therapy with CDCs that lead to 
improved cardiac function, such as cardiomyocyte proliferation, enhanced angiogenesis, and 
reduced myocardial fibrosis. Based on these preclinical investigations, a prospective phase 1a 
study of intracoronary CDC infusion was conducted and evaluated in children with DCM and 
reduced ejection fraction (EF).    
 
RESULTS 




The animal model of DCM was induced by microembolization through three-vessel 
intracoronary delivery of embolic microspheres (Fig. 1A). As an initial pilot study in 10 pigs, 
we first probed the stability of global LV dysfunction and interindividual variability using a 
dose titration test, which ranged from 0.5×104 to 1.5×104 microspheres. A total of 1.0×104 
particles was determined for injection per animal based on the hemodynamic and functional 
responses to microsphere infusion. Mortality occurred in 5 out of 48 animals on the day of 
microsphere injection and 3 pigs were excluded because the ejection function did not decrease 
to less than 50%. Forty animals survived (83.3%) with dilated LV and reduced systolic function 
and were randomized for safety and efficacy evaluation studies (Fig. 1B). Two weeks after 
coronary embolization, LVEF was significantly depressed compared with baseline by 
echocardiogram (37.6 ± 3.1% vs 61.8 ± 3.5%, P<0.001; Fig. 1C). Both LV end-diastolic and 
end-systolic dimensions were likewise increased 2 weeks after microembolization (P<0.001; 
Fig. 1, D to F). Greater myocardial fibrosis was documented by Picrosirius red staining in 
perivascular and interstitial regions of the heart after microembolization compared with sham 
controls (17.5 ± 4.0% vs 0.9 ± 0.6%, P<0.001; Fig. 1G).  
Safety and CDC dosing studies in DCM model 
To examine the procedural safety and therapeutic effects of intracoronary CDC infusion in a 
DCM model, cardiac tissues were obtained from the swine right atrium and CDCs were isolated 
and expanded using an explant culture procedure as described previously (fig. S1A) (12). 
Immunofluorescent staining and fluorescence-activated cell sorting (FACS) analyses revealed 
that swine CDCs expressed typical mesenchymal stem cell markers as we reported previously in 




expression of GATA4, insulin-like growth factor-1 (IGF1), and vascular endothelial growth 
factor A (VEGFA) but lacked the mature cardiac structural protein, cardiac troponin-I (TNNI3) 
(fig. S1D). To verify the procedural safety during intracoronary infusion of CDCs in a swine 
model of DCM, 0.9×107 CDCs were administered into three coronary arteries with or without 
balloon inflation. No animals died during CDC injection; however, CDC infusion by stop-flow 
procedure showed higher incidence of transient ischemia (P=0.008) and ventricular arrhythmia 
(P=0.048) compared with that by the non-stop-flow approach (table S1). A small increase in 
cardiac troponin-T and troponin-I concentrations was observed in both procedures but was 
limited within the peri-procedural range (fig. S2). 
To determine the therapeutic dose of CDCs in a DCM model, animals were randomly 
assigned to be treated by either intracoronary infusion of phosphate-buffered saline (PBS) as 
placebo or different doses of CDCs (0.9×107 cells calculated based on 3.0×105/kg and 1.8×107 
cells as 6.0×105/kg) using a nonocclusive procedure (fig. S3). The minimal cell dose for 
infusion was defined based on our previous clinical phase 1/2 trials conducted in patients with 
single ventricle congenital heart disease and adjusted by body weight (5, 7). The absolute 
changes in LVEF, assessed by echocardiography and cardiac magnetic resonance imaging 
(cMRI) at 1 month after protocol treatment, were significantly increased in both low- and high-
dose CDC-treated groups compared with that in placebo-treated animals (P<0.001 vs placebo; 
fig. S3A). By contrast, late gadolinium enhancement (LGE) on cMRI, as a quantifying measure 
for myocardial scar, decreased markedly in both the low- and high-dose CDC-treated groups 
relative to the placebo control (+1.1 ± 0.5% in placebo vs -4.6 ± 2.0% in low-dose CDCs vs -2.6 




infusion compared with controls was confirmed using Picrosirius red staining and showed 
similar results (fig. S3C). These CDC treatment-derived functional benefits were closely 
associated with enhanced capillary density and increased cardiomyocyte proliferation, as 
assessed by von Willebrand factor, Ki67, and phosphorylation of histone H3 immunostainings, 
respectively (fig. S3, D to F). 
CDC exosome-mediated cardiac repair 
Exosomes have been described as small extracellular vesicles that are produced by a variety of 
cell types including stem cells and may function as a vehicle to transfer microRNA (miRNA), 
mRNA, and proteins for intercellular communication (13). To test the hypothesis that exosomes 
secreted by CDCs (CDCex) could induce profound beneficial effects observed during the 
regenerative processes in a DCM model, CDCex were isolated and their molecular signatures 
were confirmed by CD9, CD63, and CD81 protein expression (Fig. 2, A to C). Raft-associated 
protein Flotillin-1 was not enriched in CDCex compared with CDC lysate, and polymeric 
cytochrome c was completely absent in CDCex as previously described (14). Pretreatment with 
GW4869, a selective inhibitor of neural sphingomyelinase, for 12 hours decreased exosome 
release from CDCs in a dose-dependent manner without affecting either the cell viability or 
replicative capacity (Fig. 2, D to F). miRNA transcriptional profiling of CDCs and CDCex 
identified several miRNAs that were markedly enriched in CDCex ,included miR-126-5p, miR-
132, miR-146a-5p, miR-181b, miR-210, and miR-451; those have been reported to induce 
antifibrotic, antiapoptotic, and proangiogenic properties via activation of endogenous cardiac 
repair mechanisms (Fig. 2G) (15). As a result of GW4869 treatment, CDCex showed a reduced 




To determine whether the therapeutic benefits of CDCs were mediated by the secretion of 
exosomes, CDCs pretreated with or without GW4869 were transplanted into DCM pigs. 
Blockade of exosome release abrogated the functional recovery and histological improvements 
by CDCs in contrast to those primed with dimethyl sulfoxide (DMSO) controls, which imparted 
the anticipated therapeutic benefits of CDCs (Fig. 3, A to C). Likewise, CDCs pretreated with 
GW4869 did not enhance vascular density or cardiomyocyte proliferation 1 month after CDC 
infusion (Fig. 3, D to F). To verify whether intracoronary administration of CDCex may 
recapitulate the therapeutic effects of CDCs in a DCM model, exosomes were isolated from a 
total of 0.9×107 CDCs and co-injected with same dose of GW4869-treated CDCs for 12 hours 
to replicate the extravasation of paracrine effectors in local microenvironment. As shown in Fig. 
3, intracoronary delivery of CDCex failed to improve cardiac function (cMRI: +3.2 ± 1.9% in 
DMSO controls vs -0.4 ± 1.9% in CDCex infusion, P=0.009; Fig. 3A), attenuate myocardial 
fibrosis (LGE: -6.2 ± 1.7% in DMSO controls vs -0.8 ± 1.6% in CDCex infusion, P<0.001; Fig. 
3B), or promote angiogenesis and cardiomyocyte proliferation (Fig. 3, D to F).  
Secretary mechanisms of exosomes in hypoxic CDCs 
Although isolated CDCex did not contain small membranous particles released from apoptotic 
bodies and were carefully analyzed by canonical exosome markers, manufactured CDCs ex vivo 
might have different secretory constituents from those of transplanted CDCs in vivo after 
certain forms of physiological stress and inflammatory processes. Whether the biological 
function of GW4869 might be affected under these pathophysiological circumstances after CDC 
infusion in an animal model of DCM remains to be tested. Our data demonstrated that CDCs 




in hypoxia-inducible factor (HIF)-1A expression, and this was not changed by GW4869 
treatment but was reduced by acriflavine (ACF) treatment, a HIF-1 inhibitor (fig. S4A) (16). 
While the blockade of exosomal secretion from CDCs by ACF was evident by hypoxia for 12 
hours, GW4869 conferred stable inhibitory effects on CDCex biosynthesis regardless the 
oxygen conditions in culture (fig. S4B). Mechanisms of CDCex-derived autocrine effects by 
growth factors were also analyzed and revealed that inhibition of HIF-1 by ACF but not 
GW4869 reduced VEGF protein concentration under normoxia or in response to hypoxia (fig. 
S4C). The concentration of insulin-like growth factor-1 (IGF1) and basic fibroblast growth 
factor (bFGF), which are known to be regulated by non-vesicular secretion (17), was unchanged 
in CDC culture medium treated with GW4869 or ACF (fig. S4, D and E). In addition, the basic 
regulatory functions for secretory miRNAs appeared to be similar in the presence of both 
exosome inhibitors (fig. S5). Consistent with previous work, our results confirmed the 
sphingolipid ceramide-dependent regulatory action of GW4869 on CDCex (17-19) and 
recapitulated the pathophysiological relevance of its secretory machinery of proteins and 
miRNAs in vitro.  
Patient enrollment and characteristics 
Our results from preclinical studies provided a clinically relevant large animal model of DCM 
to evaluate procedural safety of intracoronary infusion of CDCs using a nonocclusive approach 
and to assess functional improvement, with histological evidence of myocardial repair in CDC-
treated pigs. Motivated by these results, we proceeded to investigate clinical safety and 
therapeutic efficacy of CDC infusion in children with DCM and reduced EF. Fourteen 




pacemaker implantation, coexistence of type-B Wolff–Parkinson–White syndrome requiring 
catheter ablation, recovered cardiac function by intensive medication or cardiac 
resynchronization therapy, or advanced respiratory failure (Fig. 4 and table S2). Ultimately, 5 
DCM patients with or without LV noncompaction (LVNC) participated in the TICAP-DCM 
phase 1a trial as a treatment group (aged 11.4 ± 6.7 years; table S3). Their baseline 
characteristics and medications were generally similar, except for children with LVNC who 
showed a trend for earlier onset of heart failure compared with those without LVNC (Table 1). 
One patient without LVNC had markedly reduced LVEF (12.2%) during enrollment, indicating 
eligibility for registration on the heart transplant listing, but this patient refused to wait for 
transplant due to religious reasons (Table 1).  
Safety evaluation 
All participants had evident reduced LVEF (<40%) assessed by echocardiogram and cMRI, as 
required for enrollment. Endomyocardial biopsy specimens were obtained from individual 
patient, minced into explants, cultured, and passaged 3 to 4 times to achieve the prespecified 
CDC dose (3.0×105/kg) within 31.8 ± 4.7 days for injection after quality control validation (fig. 
S6). Although creatine kinases remained below the safety threshold, 4 out of 5 serum 
concentrations of cardiac troponin-T and -I were minimally elevated 1 day after CDC infusion 
but diminished over the 6 months of follow-up (fig. S7). No incidence of thoracic ectopic tissue 
formation was observed by cardiac imaging and biomarker analyses. There was one case of 
transient ischemia associated with CDC infusion (Table 2). This patient had serious adverse 
events including advanced heart failure and lung infection within 24 hours after CDC injection 




coronary syndrome or sustained ventricular arrhythmia during 12 months of follow-up (Table 
2). 
Cardiac function and heart failure status 
Inotropic therapy used in 2 patients during study enrollment could be discontinued after CDC 
infusion (Table 1). Although this TICAP-DCM phase 1a trial was not considered to detect 
therapeutic efficacy on the basis of statistical power estimation, cardiac function and heart 
failure status were evaluated from baseline to 6- and 12-months of follow-up after CDC 
infusion as preliminary results of secondary outcomes. Compared with baseline, there was a 
nonsignificant trend for improvements in LVEF assessed by cMRI at 6- and 12-months post 
CDC treatment (EF: 26.4 ± 7.8% at baseline vs 31.5 ± 10.2% at 6 months vs 31.8 ± 9.4% at 12 
months; P=0.067, Fig. 5A). Both end-diastolic and end-systolic volumes did not differ from 
baseline over 12 months of follow-up (Fig. 5B, P=1.0; Fig. 5C, P=0.689, respectively). 
Quantitative analysis of LGE and native T1 mapping also supported that functional recovery 
might be mediated through a reduction in the extent of myocardial fibrosis (LGE: 3.0 ± 2.0% at 
baseline vs 2.4 ± 1.6% at 12 months; P=0.248, Fig. 5, D and E) and extracellular volume 
fraction in patients treated with CDCs (native T1: 1041.6± 60.4 ms at baseline vs 984.8 ± 39.3 
ms at 12 months, P=0.025; Fig. 5, F and G). Echocardiographic measurements revealed that 
CDC infusion increased the LVEF at 12 months (EF: 28.5 ± 10.7% at baseline vs 33.0 ± 11.1% 
at 12 months, P=0.038; Fig. 5H), whereas both end-diastolic and end-systolic volumes remained 
unchanged (Fig. 5I, P=0.980; Fig. 5J, P=0.528, respectively). B-type natriuretic peptide (BNP) 
amount did not differ (BNP: 205.2 ± 350.2 pg/mL at baseline vs 186.2 ± 319.7 pg/mL at 12 




York University pediatric heart failure index (NYUPHFI) classifications from baseline during 
12 months of observation (Ross score: 2.4 ± 1.1 at baseline vs 1.8 ± 1.3 at 12 months, P=0.135; 
NYUPHFI: 11.4 ± 6.9 at baseline vs 9.0 ± 6.3 at 12 months, P=0.306; Fig. 5, K to M). 
CDCex-derived miRNAs and reduction of myocardial fibrosis in patients with DCM 
To further assess how transplanted CDCs confer therapeutic benefits in enrolled participants, we 
performed miRNA analysis on the small RNA fraction of CDCs and CDCex isolated from 
individuals and compared with that of human cardiac fibroblasts (HCFs). Patient-derived 
CDCex exhibited high expressions of CD9, CD63, and CD81 as measured by flow cytometry 
(Fig. 6, A and B). Flotillin-1 was ubiquitously present in both CDC fractions (Fig. 6C) but 
polymeric cytochrome c was barely detected in CDCex. CDCex were enriched in several 
miRNAs that have been previously shown to exert cardioprotective effects (15). Among the 
transcriptional targets, 5 miRNAs were specifically enriched in CDCex, including miR-126-5p, 
miR-132-3p, miR-146a-5p, miR-181b, and miR-210-3p, whereas miR-451a was enriched in 
both CDCex and HCFex (Fig. 6D). We investigated whether the transcriptional expression of 
the individual CDCex-derived miRNAs correlated with cardiac functional improvement after 
CDC treatment. The expressions of exosomal miR-146a-5p, but not miR-451a, were positively 
correlated with the reduction in both myocardial fibrosis (r=0.886, P=0.045) and extracellular 
volume fraction (r=0.896, P=0.040) at 12 months of follow up (Fig. 6E and fig. S8A). 
miR-146a-5p inhibits inflammatory responses in human cardiomyocytes 
To gain further insight into the physiological role of miR-146a-5p in myocardial inflammation 
and fibrosis, human AC16 cardiac cells were stimulated with TNF-a, a potent proinflammatory 




cardiomyopathy (20). Undifferentiated AC16 cells exposed to TNF-a for 12 and 24 hours 
resulted in an increase in miR-146a-5p expression (fig. S8B). To better understand the 
functional effects of miR-146a-5p, human AC16 cells were transfected with either 
overexpressed miR-146a-5p (mimic), antagonized miR-146a-5p (antagomir), or corresponding 
transfection controls (fig. S8, C and D). Transduction of mimic miR-146a-5p but not antagomir 
miR-146a-5p reduced TNF-a-induced cardiac apoptosis relative to scramble control (16.3 ± 
1.3% vs 30.7 ± 6.1%: P=0.003; Fig. 6F and fig. S8E). TNF-a activated proinflammatory 
cytokines such as interleukin (IL)-6 that was inhibited by miR-146a-5p overexpression but 
enhanced by antagomir to miR-146a-5p compared with controls (Fig. 6G and fig. S8F). On the 
other hand, miR-146a-5p reduced the expression of TNF receptor-associated factor 6 (TRAF6), 
SMAD4--a central mediator of transforming growth factor (TGF)-b signaling, and proto-
oncogene FOS in the presence or absence of TNF-a (Fig. 6G), whereas blocking the miR-146a-
5p by antagomir blunted most of those biological effects (fig. S8F). However, miR-146a-5p-
mediated post-transcriptional regulation of FOS expression after TNF-a stimulation was 




Pediatric DCM is a rare disease but has become a leading cause of advanced heart failure, 
constituting the largest subpopulation of patients undergoing heart transplantation (21). DCMs 
in adults and children have similar structural and functional manifestations but are characterized 




on adult DCM, whereas extrapolating the evidence for therapeutic efficacy from adults to 
children often failed to confirm the benefits, and some delivery modalities may be neither 
feasible nor safe in children (23). Idiopathic DCM is estimated to occur in 50-70% of children 
with DCM; however, preclinical studies constructed to advance cell therapies to treat patients 
with pediatric DCM are still at an early stage of development due to the difficulty of disease 
modeling in large animals and limited by a varied range of disease classifications in children 
(24). The strengths of our preclinical study compared with previous assessments of therapeutic 
efficacy in stem cells could be the modeling of secondary DCM in large animals, dose titration 
to determine optimal cell dosage, and defining the possible mechanisms contributing to cardiac 
repair in DCM. 
Increasing investigation of the pediatric DCM population by genetic analysis may suggest 
intervention strategies and predict disease severity. Doxorubicin- or tachycardia-induced 
cardiomyopathies have been reported to reconstitute the pathogenesis of secondary DCM in 
large animal studies (25, 26). These two experimental models have the advantage of producing 
a physiologically and morphologically relevant DCM model that closely resembles humans, but 
sudden cardiac death was frequently observed during anthracycline overload (n=10, qualified 
survival rate: 30%), and tachycardia-induced systolic dysfunction (n=5, qualified survival rate: 
100%) was reversible by terminating the chronic pacing in our pig experiments (reversibility: 
80%). Although DCM secondary to global myocardial ischemia is common in adults rather than 
in children as a form of acquired atherosclerosis, the causes of pediatric dilated cardiomyopathy 
leading from acquired myocardial ischemia are relatively rare. There are some common aspects 




cardiac allograft vasculopathy from heart transplantation (1). The empirical results of our 
preclinical study by coronary vessel microembolization produced a highly reproducible 
microinfarction model with global myocardial remodeling. However, the major limitation of our 
study might be the differential nature of pathogenesis between ischemic and nonischemic DCM 
during the preclinical investigation towards clinical translation.  
In contrast to ischemic DCM, patients with nonischemic DCM exhibit a greater amount of 
dysfunctional but viable myocardium with a lesser extent of myocardial fibrosis, which may 
contribute to adverse remodeling. This differential disease pathogenesis during heart failure 
progression may reflect distinct disease mechanisms between adult and pediatric DCMs and 
also suggest that cell therapy may be appropriate for children with DCM (22). Recent progress 
in clinical studies has raised pivotal questions with respect to the optimized cell dose and 
delivery modality for pediatric DCM (27). Whether cell infusion with interrupted coronary flow 
is necessary for therapeutic efficacy remains uncertain but has been shown to increase the risks 
of adverse coronary events. The study design of our preclinical investigation rigorously 
evaluated the procedural safety and therapeutic efficacy of a nonocclusive intracoronary 
infusion approach at prespecified endpoints in a clinically relevant large animal model of DCM. 
Our results are consistent with the previous study performed in a swine model of single vessel 
myocardial infarction (28). In addition, a dose-escalation study is essential for clinical 
translation but has been poorly defined in DCM models. Our data provide a strong rationale for 
the clinical dosage to deliver in patients with DCM and that is consistent with the cell dose 
applied in children with single ventricle physiology in the TICAP and PERSEUS phase 1/2 




Cardiac functional improvements in our preclinical study were associated with enhanced 
angiogenesis, increased endogenous cardiomyocyte proliferation, and reduced myocardial 
fibrosis; however, these observations cannot be appreciated solely by the direct engraftment and 
differentiation of transplanted CDCs (29). From this perspective, the results of our preclinical 
study suggested that CDC-derived paracrine factors such as exosomes might exert therapeutic 
benefits during the processes of cardiac repair (15). Although determining the specific exosome 
content that might be involved in extracellular communication by high throughput analysis 
remains particular challenging, blunting exosome secretion from CDCs abrogated the beneficial 
effects in the transplanted DCM hearts, supporting our hypothesis that a subset of miRNA, 
mRNA, and proteins secreted through CDCs might participate in the process of functional 
recovery. The blockade of exosome secretion with GW4869 is independent of the endosomal 
sorting complexes required for transport machinery but regulated by a sphingolipid ceramide-
dependent pathway (18). A plausible mechanism of cardiac repair processes through vesicular 
secretion that does not depend on the Golgi apparatus or a subset of cytokines and signaling 
substances released through non-vesicular pathways cannot be excluded (17). 
Consistent with previous reports, our results also confirmed that intracoronary delivery of 
CDCex alone was not sufficient to reproduce the beneficial paracrine effects of CDCs, perhaps 
because of a lack of efficient cardiac lodging due to the vesicle size (30). The quick intracellular 
uptake of exosomes, which might be dependent on the interplay between cell source and target 
cells to uptake the circulating vesicles, results in rapid CDCex clearance within the heart (31). 
In this regard, exosome secretion directly from the delivered CDCs at the site of cardiac 




sufficient uptake of biologically active exosomes within the heart after intracoronary delivery of 
CDCex is one of the limitations in our preclinical study. Notwithstanding, optimal CDCex-
based therapies would warrant further development of advanced technologies to incorporate the 
exosomes with a specific binding partner within the cardiac niche to activate endogenous 
myocardial repair processes. 
Recent studies demonstrated that CDCex enriched in miR-146a-5p inhibited myocyte 
apoptosis and fibrosis, enhanced neovascular formation, and augmented cardiac function after 
infarction (19, 32). Moreover, exposure to CDCex enabled fibroblasts to alter their intrinsic 
biological signals into distinct miRNA signatures included miR-146a-5p as therapeutic cells to 
restore cardiac function after injury (33). miR-146a-5p has been reported as a negative feedback 
mediator of nuclear factor-kB signaling through the transcriptional targeting of downstream 
effector components of its activation, including TRAF6 and IL-1 receptor associated kinase 1 
(IRAK1) (34). SMAD3/4 cooperated with FOS to activate transcription in response to TGF-b-
mediated inflammatory signaling at heterodimeric activator protein-1 binding site to exert 
potent effects on extracellular matrix remodeling (35). Consistent with this interpretation, 
increased intrinsic expression of miR-146a-5p in CDCex may have cardioprotective effects on 
inflammatory responses as an efficient CDC-based postconditioning in patients with DCM. 
Although our results demonstrated that miR-451a expression was similar in both HCFex and 
CDCex, its biological function might differ by the pathogenesis of cardiomyopathy (36, 37). 
Therefore, careful investigation of the physiological state of the parental cell of origin as well as 
the constituents of the exosomal contents would be required to define their intrinsic functions in 




CDCex carrying cardioprotective miRNAs as potential prognostic biomarkers for cell therapy 
(38). 
Of particular note, CDC- and CDCex-mediated myocardial repair in vitro and in vivo has 
been shown to be dependent on the donor’s age, suggesting that donor CDCs and CDCex from 
children rather than adults might be beneficial as therapeutic applications (11, 39). A 
comprehensive characterization of CDCex cargo to uncover the pharmacokinetics of CDCex 
may offer a fundamental advantage to enhance therapeutic efficacy in the injured heart for 
therapeutic success in the future (40).   
  This TICAP-DCM phase 1a study was conducted as an open-label, pilot, prospective trial at a 
single center. Due to the low annual incidence of pediatric DCM, the study was inevitably 
closed with a final enrollment of 5 participants out of a prespecified total of 7 without control 
patients for longitudinal comparison and limited to validation of the procedural feasibility and 
safety of intracoronary delivery of CDCs in children. The heterogenous population of patients 
with DCM with mixed cardiac phenotypes or diagnosed with insufficient genetic screening 
might also affect the safety profile and therapeutic responses after CDC infusion (41, 42). Of the 
5 children with DCM, minimal Troponin-T and -I elevations were observed within the peri-
procedural range in 4 patients. One had serious adverse events, including congestive heart 
failure and lung infection, and required acute circulatory support for recovery after CDC 
infusion. This patient was at the highest risk of death and heart transplantation based on 
increased LV end-diastolic dimension, severity of LV dysfunction, and older age at diagnosis 




44). Our experience has provided insights into an eligibility algorithm in children with 
intractable advanced heart failure without transplantation as a treatment option.  
In our preclinical study, several mechanisms have been proposed to interpret the therapeutic 
benefit in children with DCM treated with CDCs, including increased neovascularization, 
myocyte proliferation, and reduction in myocardial fibrosis. Replacement fibrosis by cardiac 
scarring that developed in a discrete area of the myocardium as a result of myocyte cell death 
has been recognized as one of the pathological features of DCM. Although both LGE and T1-
mapping measurements using cMRI have emerged as diagnostic methods to provide prognostic 
information of regional or diffuse myocardial disease for risk stratification, limited studies are 
available in children with heart disease (45). In our phase 1a clinical study, children with LVNC 
were excluded from quantitative T1-mapping analysis to measure the substantial fraction of 
myocardial extracellular volume, because the small and discrete regions of interest in thin 
ventricular wall segments with excessive trabeculations may lead to artificially high values. 
Conversely, pixel-wise mapping native T1 relaxation times were calculated to determine the 
degree of diffuse myocardial fibrosis (46, 47).  
  The preclinical study presented in this report was initiated to determine the clinically relevant 
optimal dosage of intracoronary delivered CDCs in a large animal model of DCM with 
widespread myocardial dysfunction. The procedural feasibility was confirmed using a 
nonocclusive coronary infusion approach with a satisfactory safety profile compared with 
conventional stop-flow delivery into 3 coronary arteries. CDC treatment in a DCM model was 
associated with improved myocardial function, increased neovascularization, cardiomyocyte 




therapeutic benefits could be completely abolished by blunting exosomal release of 
proangiogenic and cardioprotective miRNAs, including miR-146a-5p targeting of 
TRAF6/SMAD4/FOS for post-transcriptional repression, through the transplanted CDCs. 
Following rigorous preclinical investigations, the TICAP-DCM phase 1a trial was approved and 
conducted as a prospective clinical study with intracoronary infusion of CDCs in children with 
DCM. Our results during 1-year of follow-up indicate that CDCs are safe for the pediatric 
population and warrant continued study as an efficacy evaluation by the TICAP-DCM 
randomized-controlled phase 1b trial in children with DCM who have reduced ejection function 
but limited therapeutic options.  
 
MATERIALS AND METHODS 
Study design and outcome measures 
The clinical study was registered as NCT03129568 (ClinicalTrials.gov). Individual subject-
level data are provided in data file S1. The TICAP-DCM (Transcoronary Infusion of Cardiac 
Progenitor Cells in Pediatric Dilated Cardiomyopathy) phase 1, open-label trial was conducted 
at Okayama University Hospital between July 24th, 2017, and September 17th, 2018. The study 
design and protocol were approved by the Ethics Committee of Okayama University 
(01F1701003) and followed the Guidelines on Clinical Research Using Human Stem Cells 
issued by the Ministry of Health, Labour and Welfare, Japan. This trial was performed in 





Children aged less than 18 years with a diagnosis of DCM based on clinical and 
echocardiographic findings were screened and the study enrollment required evidence of LV 
dilation with reduced EF defined as less than 40% (1). Although neuromuscular, mitochondrial, 
syndromic, and metabolic causes were considered to be further validated by genetic screening, 
sarcomeric mutation analysis was not performed in patients with cardiomyopathy with either 
isolated or LVNC phenotype. Exclusion criteria included cardiogenic shock, intractable 
arrhythmias, repeated infections, advanced renal or hepatic dysfunction, and manifested cancer 
diseases. Mixed hypertrophic or restrictive cardiomyopathy phenotypes were also excluded. 
Every eligible participant was subjected to endomyocardial biopsies to obtain sufficient 
specimens for pathological diagnosis and CDC culture. Patients classified as secondary DCM, 
such as inflammation, toxic exposure, metabolic disorders, and structural heart disease, were not 
enrolled in this trial.  
The TICAP-DCM prospective, open-label, phase 1 trial comprised of a phase 1a study (n=5, 
prespecified as 7 but limited to 5 patients available for recruitment due to the disease severity 
and rarity) to evaluate procedural safety during intracoronary delivery of CDCs (3.0×105/kg) 
using nonocclusive approach, and a phase 1b study (n=24, in a 1:1 randomization) to assess the 
therapeutic benefits. The sample size was determined based on a power of 85% to detect a 
difference of 4.5% in the cardiac function, assuming that the common standard deviation is 
3.5% between controls and CDC-treated groups using a 2-group t test at 2-sided. Study 
participants were assessed at baseline, 6, and 12 months of follow-up. The primary safety 
endpoint was adverse events occurring in the treatment arm including ventricular fibrillation, 




formation after CDC infusion (5). The secondary endpoint was to assess the functional 
improvement of the global cardiac function and heart failure status from baseline to 6 months of 
follow-up, as described previously (7). The study participants were closely monitored by an 
independent data monitoring committee at the Center for Innovative Clinical Medicine. Data 
management board at Translational Research Center for Medical Innovation (Kobe) has verified 
and vouched for the accuracy, completeness, and fidelity of the clinical data.  
Animal model and randomization 
The animal experimental protocols were approved by Okayama University Institutional Animal 
Care and Use Committee (OKU-2019058). All animals received humane animal care in 
compliance with the “Guide for the care and use of laboratory animals” published by Okayama 
University. Experiments were descriptive and exploratory without power consideration to 
determine the sample size. Fifty-eight female Yorkshire pigs of 25-35 kg in weight and at an 
age of 8-week-old were anesthetized by intramuscular injection of ketamine (10 mg/kg), 
xylazine (2 mg/kg), and atropine sulfate (0.5 mg), intubated, and placed on a ventilation system 
(ACOMA, PRO-45). Continuous sedation was maintained using a closed-circuit system with 
inhalation of 2% isoflurane. The DCM model characterized by global dilation and systolic 
dysfunction was generated by transcoronary injection of embolic agent that was made of tris-
acrylic copolymer impregnated in porcine gelatin (Embosphere: 100–300 µm in diameter; 
Biosphere Medical) with modifications (48). A 6-French Hockey Stick or Judkins Right 
catheter (Medtronic, Minneapolis) was introduced and distal coronary selection was achieved 
using a high-flow type microcatheter (Akatsuki; Gadelius Medical). A total of 1.0×104 




infused into three coronary arteries over 5 minutes for each injection (5 mL per coronary 
artery). Cardiac function was evaluated 2 weeks after microembolization, and qualified animals 
were randomly assigned to be treated by intracoronary infusion of PBS as placebo controls 
(n=5) or allogeneic CDCs (n=35) for cell dosing and function studies as indicated. 
CDC delivery 
Human and swine CDCs were isolated, manufactured, and validated as described in 
Supplementary Methods and table S4. Grown CDCs were resuspended in 0.1% heparin 
containing PBS in a total 15 mL volume and divided into 5 mL aliquots for each administration. 
In pig experiments, intracoronary injection of placebo or either 0.9×107 or 1.8×107 allogeneic 
CDCs was performed 2 weeks after coronary microembolization using a KUDOS balloon 
catheter (Fuji Systems) with either 3-minute balloon inflation (stop-flow procedure) or 5-minute 
deflation (nonocclusive procedure) cycles during three-vessel infusions. Myocardial ischemia 
was monitored by electrocardiogram and serum troponin-T/I measurement on the day and 24 
hours after CDC infusion. 
Histology 
Paraffin-fixed ventricular rings were sectioned at 5 µm, deparaffinized, and stained with 
Picrosirius red (Polysciences, Warrington) and hematoxylin and eosin (H&E) to analyze the 
magnitude of cardiac fibrosis. Ten random images from each treatment group were captured and 
the percentage of myocardial fibrosis per image was quantified by using hybrid cell count 
system of BZ-X Analyzer. To evaluate microvascular density and myocyte proliferation, 
sections were stained with rabbit polyclonal antibodies against von Willebrand factor (ab6994), 




antibody against myosin heavy chain (MA1-26180, Thermo Fisher Scientific) at 1:100 dilution. 
Alexa Fluor 488 goat anti-rabbit IgG, and Alexa Fluor 546 goat anti-mouse IgG (Thermo Fisher 
Scientific) were incubated as secondary antibodies (1:200 dilution), and nuclei were visualized 
with 4’,6-diamidino-2-phenylindole (DAPI). The stained slides were evaluated in stacked 
images using a BZ-X710 Analyzer (KEYENCE). 
Exosome preparation 
CDCex isolation was performed as described previously with modifications (30). In brief, 
allogeneic swine or autologous human CDCs were washed and transferred to serum-free 
IMDM. After 48 hours, the conditioned medium was harvested, centrifuged for 20 minutes at 
2,500 × g, and filtered through a 0.22 µm GV filter (Millex). The supernatant was transferred to 
an Ultra-15 centrifugal filter (10K; Amicon) after equilibration of the membrane with PBS by 
centrifugation at 4,000 × g for 10 minutes. CDCex were then isolated and concentrated by 
repeated centrifugation at 4,000 × g for 30 minutes and the exosomes pellet was resuspended in 
PBS solution for assays. CDCex obtained from 2.0×106 CDCs were diluted in 500 µl PBS and a 
total of 3 µl of CDCex-containing buffer was loaded onto a carbon-Formvar-coated copper grid, 
stained with uranyl acetate solution, and dried for scanning transmission electron microscopy 
(Hitachi H7650 TEM). The exosomes were characterized for size distribution and quantitated 
by NanoSight NS300 (Malvern Panalytical). CDCex inhibition was induced for 12 hours by 
either 20 µM GW4869 (Sigma-Aldrich), a selective inhibitor of neural sphingomyelinase, or 5 
µM acriflavine (ACF; Sigma-Aldrich), a HIF-1 inhibitor. The cell viability was assessed using a 
trypan blue exclusion assay (Sigma Chemical Company). 




Swine CDCs were validated using the following primary and secondary antibodies: mouse 
monoclonal or rabbit polyclonal antibodies against CD90 (ab123511), CD105 (ab69772), CD31 
(ab186720), and CD45 (ab10559); FITC-goat anti-mouse/rabbit antibodies (BD Pharmingen) 
and Alexa Fluor 546 or 488 goat anti-mouse/rabbit IgG (Thermo Fisher Scientific). 
Immunofluorescence and flow cytometric analysis (FACS) were performed in accordance with 
the methods used in human CDC validation (5). The human CDCex were validated by flow 
cytometry using an ExoCap Streptavidin Kit (MBL life science) according to the 
manufacturer’s protocols. Magnetic microbeads coated with biotinylated-CD9, -CD63, or -
CD81 antibodies were used to recognize the surface antigens. The fluorescent signals were 
detected by streptavidin-FITC conjugated antibody (Miltenyi Biotec Inc) using FlowJo. 
Microbeads incubated with an antibody in the absence of exosomes served as control. TNF-a 
(Cell Signaling Technology)-treated AC16 cells were double-stained with 5 µL annexin V and 5 
µL propidium iodide using annexin V-FITC apoptosis detection kit (eBioscience) and 
myocardial apoptosis was evaluated by FACS.  
Immunoblotting 
The primary and secondary antibodies used for validation of CDC lysate or CDCex obtained 
from pigs and humans were as follows: rabbit polyclonal anti-CD9 (LS-C135937-100, LSBio); 
goat polyclonal anti-CD63 (ABIN1440014, antibodies-online Inc.); rabbit polyclonal anti-CD81 
(AI14938, Abgent); goat polyclonal anti-Flotillin-1 (ab13493); rabbit polyclonal anti-
cytochrome c (ab90529); mouse monoclonal anti-glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH; ab8245); and goat anti-rabbit/horse anti-mouse (Cell Signaling Technology) /donkey 





Descriptive data are presented as absolute numbers and percentages or means and SDs. 
Significance of differences between two treatment groups was assessed using Student’s t-test. 
Paired t-test was used to determine the significance between baseline and an endpoint within a 
group. For multiple comparisons of continuous measures between groups, the Kruskal-Wallis 
test was used if normality could not be established. When the variables were distributed 
normally, one-way analysis of variance (ANOVA) was performed and Tukey post hoc test was 
applied to determine the statistical significance between groups. Categorical variables presented 
by the number of observations between the groups were compared using Fisher exact test. 
Individual comparisons at baseline to 6 and 12 months of follow-up were analyzed by one-way 
ANOVA with repeated measures followed by Dunn–Bonferroni post hoc correction according 
to the data normality. The Friedman test was used to analyze the heart failure status in CDC-
treated patients from baseline to 12 months of follow-up and Wilcoxon signed-rank test with 
Dunn–Bonferroni post hoc correction was applied to compare the changes from baseline. Linear 
regression analysis using Pearson’s correlation coefficient was applied to evaluate the 
relationship between absolute changes in the extent of myocardial fibrosis from baseline to 12 
months of follow up and the expressions of CDCex-derived miRNAs, and r values were 
presented as Pearson product-moment correlation coefficient. A P value less than 0.05 was 
considered to be significant. Analyses were conducted using SPSS software (version 26, IBM 
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(A) Schematic and representative brightfield microscopic images of microspheres used for 
selective coronary injection to achieve global cardiac dysfunction by microembolization. (B) 
Preclinical study design to explore the procedural safety and therapeutic efficacy of 
intracoronary cardiosphere-derived cell (CDC) infusion in a swine model of DCM. Severely 
depressed global function (C) and dilated ventricular volumes (D and E) were noted 2 weeks 
after coronary microembolization (n=40). EDD, end-diastolic dimension. ESD, end-systolic 
dimension. (F) Representative images of echocardiograms during microembolization. (G) 
Picrosirius red staining and quantification of diffuse myocardial fibrosis in swine model of 
DCM. White arrow in inset shows a microsphere embolized in a capillary vessel. Scale bar, 200 
µm in (A); 10 mm in (F) and (G); and 300 µm in inset. Data were analyzed using paired t-test 











(A) Exosomes isolated from porcine CDCs were visualized using an electron microscope. Three 
different exosomes are shown. Scale bar, 50 nm. (B) Size distribution and particle number were 
assessed by nanoparticle tracking analysis. (C) CDCex were verified by immunoblotting of 
CD9, CD63, CD81, Flotillin-1, and cytochrome c (Cyt c) and compared with CDC lysate (n≥3). 
Dose-dependent effects of pre-incubation with GW4869 for 12 hours on (D) exosome release in 
CDCs (n=3), (E) CDC viability (n=3), and (F) cell growth kinetics in 20 µM GW4869 
treatment up to 7 days in culture (n=6). CDCs treated with hydrogen peroxide for 4 hours was 
used as a positive control. (G) CDCs were treated with either DMSO or 20 µM GW4869 for 12 
hours and the relative expressions of miRNAs in CDCs and CDCex compared with that of 
DMSO-treated CDCs were analyzed by real-time RT-PCR (n=5). Let-7a was used as an internal 
control. DMSO, dimethyl sulfoxide. Statistical significance was determined using one-way 











Two weeks after microembolization, DCM pigs were randomly allocated to be treated with 
0.9×107 CDCs pre-incubated with either DMSO or GW4869 with or without co-injection of 
CDCex isolated from 0.9x107 CDCs. (A) Cardiac function was analyzed 1 month after 
treatment using ultrasound echocardiogram (UCG, top) and cMRI (bottom). Absolute changes 
in LVEF from baseline to 1 month of follow-up are shown. Myocardial fibrosis was analyzed 
using LGE (B) and Picrosirius red staining (C). Capillary density and cardiomyocyte 
proliferation were monitored using von Willebrand factor (vWF, D), Ki67 (E), and phospho-
histone H3 (PHH3, F) immunofluorescence in hearts after intracoronary injection of 0.9×107 
CDCs pre-incubated with either DMSO or GW4869 (20 µM) with or without co-injection of 
CDCex isolated from 0.9x107 CDCs. Heart sections were counterstained with myosin heavy 
chain (MyHC) to visualize cardiomyocytes and DAPI (4′,6-diamidino-2-phenylindole) nuclear 
marker. Green arrows show Ki67 or PHH3 positive cardiomyocyte. MyHC negative non-
cardiomyocytes expressing either Ki67 or PHH3 were shown by blue arrows. Scale bar, 10 mm 
in (B) and (C); 50 μm in (D); and 200 μm in (E and F). Statistical analysis was performed by 







Fig. 4. Study flow chart of TICAP-DCM phase 1 trial. 
The TICAP-DCM trial was composed of two stages. The primary objective was to investigate 
the procedural safety of intracoronary infusion of CDCs (3.0×105/kg) by non-stop-flow delivery 
approach in 5 patients with DCM and reduced ejection fraction as an open-label, lead-in phase 
1a study. The second stage was an open-label, randomized-controlled (1:1 ratio) study to 
evaluate the therapeutic efficacy of CDC infusion in 24 patients with similar eligible criteria 
(Phase 1b study). The secondary endpoint analysis was to assess the absolute changes in cardiac 
function and myocardial fibrosis in patients 6 months after CDC treatment compared with 
control participants treated by standard medication alone. WPW, Wolff–Parkinson–White. 
CRT, cardiac resynchronization therapy. Recovered cardiac function is determined by LVEF 







Fig. 5. Cardiac function analysis and heart failure status in the TICAP-DCM phase 1a 




(A to C) Ventricular function and end-diastolic and end-systolic volumes were assessed using 
cMRI from baseline over 12 months. EDVI, end-diastolic volume index. ESVI, end-systolic 
volume index. Individual participant data are shown. Myocardial fibrosis was analyzed using 
LGE (D) and native T1 mapping (F) in DCM patients with or without LVNC. (D) Mid-wall 
fibrosis was detected using LGEs with mid-myocardial distribution in the interventricular 
septum and highlighted with yellow arrows. The deep intertrabecular recesses in a DCM patient 
with LVNC are shown (white arrows). Scale bar, 20 mm. (E) Regional myocardial fibrosis was 
analyzed using the extent of LGE in 5 patients treated by CDC infusion from baseline to 12 
months of follow-up. (F) Representative images of native T1 mapping revealed prominent 
trabeculations and interventricular recesses in a DCM patient with LVNC. (G) Diffuse 
myocardial fibrosis was evaluated using native T1 mapping in 5 study participants from 
baseline to 12 months after CDC treatment. (H to J) Left ventricular function and volumes were 
assessed using an echocardiogram from baseline over 12 months after protocol treatment. Heart 
failure status was monitored by plasma BNP concentrations (K), Ross score (L), and NYUPHFI 
classification (M) from baseline to 12 months of follow-up. Data were analyzed by one-way 
analysis of variance with repeated measures followed by Dunn–Bonferroni post hoc corrections 







Fig. 6. miR-146a-5p reduced myocardial inflammation and apoptosis through 




Exosomes were isolated from study participant-derived CDCs and characterized by 
transmission electron microscopy (A), flow cytometry (B) and immunoblotting (C). 
Representative images are shown. Scale bar, 50 nm in (A). (D) Relative miRNA expression in 
human CDCs and CDCex from individual patient compared to that of human cardiac fibroblasts 
(HCFs) are shown (n=5). U6 was used as an internal reference for normalization. (E) 
Correlations between the changes in myocardial fibrosis (-ΔLGE) or extracellular volume 
fraction (-ΔNative T1) in individual participants at 12 months compared with baseline and 
CDCex-derived miR-146a-5p expression relative to U6 (-ΔCT) are shown. (F) Human 
cardiomyocyte apoptosis was assessed by FACS in AC16 cells treated with TNF-a (200 ng/mL) 
for 48 hours after transduction of either mimic miR-146a-5p, antagomir to miR-146a-5p, or 
scramble as corresponding transfection controls (n=5). (G) Post-transcriptional regulation of 
miR-146a-5p targeting downstream effectors were analyzed by real-time RT-PCR in human 
AC16 cardiac cells treated with or without TNF-a (100 ng/mL) for 24 hours (n=5). Human b2-
microgloblin was used as an internal control. Statistical significance was determined using 
paired t-test or one-way analysis of variance followed by Tukey multiple comparisons. The 





Table 1. Characteristics of study participants in TICAP-DCM phase 1a trial. 
Patient 
number 






















14 years,  
9 months 












12 years,  
4 months 













6 years,  
11 months 
I 23.2 14.9 Carvedilol 




3 months II 33.2 42.8 Carvedilol; 
furosemide; 
spironolactone 









Periprocedural death 0 
Periprocedural ST elevation 1 
Periprocedural BP↓ (>20 mmHg) 0 
Periprocedural ventricular arrhythmia 0 
Overall deaths 0 
Heart failure 1 
Myocardial infarction 0 
Ventricular tachycardia >30 seconds 0 
Transient ECMO support 1 
Infection 1 
Incident malignancy 0 
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Materials and Methods 
Cardiac function analysis 
Echocardiography was performed to assess LV function in pigs using an Aplio300 (Toshiba 
Medical Systems) with a 5 MHz sector transducer. Cardiac magnetic resonance imaging (cMRI) 
was performed using a 1.5-Tesla scanner with 8-channel cardiac array coil (GE Healthcare). 
Contiguous short-axis cine images from the cardiac base to apex were acquired to quantify LV 
volume and function using a steady-state-free precession sequence (parameters: TR 3.6 msec; 
TE 1.6 msec; field of view 30×30 cm; slice thickness 8 mm; gap 0 mm; data matrix 224×224; 
and flip angle 45°) and then analyzed on a commercially available workstation cvi42 (Circle 
Cardiovascular Imaging Inc).  
LGE images were acquired 10 minutes after intravenous injection of gadoteridol (0.2 mM/kg 
body weight; ProHance: Eisai) using an electrocardiogram-gated inversion recovery T1 turbo 
field echo sequence (parameters: TR 6.6 msec; TE 3.2 msec; field of view 30×22.5 cm; slice 
thickness 8 mm; gap 0 mm; data matrix 256×192; and flip angle 20°). The extent of enhanced 
myocardium was assessed on a 17-segment cardiac model using short axis slices and defined by 
a semi-automatic thresholding method as myocardium with a signal intensity cut-off value of 5 
or more standard deviations (SDs) above the mean of remote myocardium (7). All images 
underwent blinded evaluation by two experienced operators. 
Cell culture  
Human CDCs were generated from right ventricular endomyocardial biopsy specimens, 
expanded in Dulbecco’s modified Eagle medium (DMEM)/F12 medium containing 10% fetal 




40 ng/mL basic fibroblast growth factor (Wako Co. Ltd.) at a Good Manufacturing Practice 
facility in Okayama University Hospital, and characterized as described previously (5, 12). In 
animal experiments, allogeneic CDCs were isolated and manufactured from 5 independent male 
porcine donors at an age of 8-week-old. The right atrial tissue was surgically collected from 
Yorkshire pigs, cut into small pieces, and grown as explant cultures on dishes (Falcon, 353004) 
in Iscove’s modified Dulbecco’s medium (IMDM; Thermo Fisher Scientific) containing 20% 
FBS, 2 mM L-glutamine (Thermo Fisher Scientific), 0.1 mM 2-mercaptoethanol (Wako Co. 
Ltd.), and 1% penicillin and streptomycin (Thermo Fisher Scientific). The cells surrounding the 
adherent explants were then harvested and reseeded at 5×104 cells/mL onto poly-D-lysine-
coated dishes. After several days, detached cardiospheres were collected and expanded in 20% 
FBS containing IMDM on culture dishes (Falcon, 353003). Human cardiac fibroblasts (HCFs; 
PromoCell) were purchased and cultured on dishes (Falcon, 353003) with fibroblast growth 
medium 3 (PromoCell). 
Transfection and hypoxia 
Undifferentiated human AC16 cells (Millipore) were maintained in DMEM/F12 supplemented 
with 12.5% FBS and were transfected with mimic miR-146a-5p (MC10722), antagomir to miR-
146a-5p (MH10722), or corresponding negative controls (mirVana miRNA mimic negative 
control and mirVana miRNA inhibitor negative control; all purchased from Invitrogen) using 
lipofectamine RNAiMAX in serum-free Opti-MEM medium (Thermo Fisher Scientific). 
Transfection efficiency was determined 24 hours after transfection by real-time RT-PCR. 
Hypoxic condition was conducted at 370C in a hypoxic workstation (BIONIX-3 hypoxic culture 




concentration at 1% for 12 hours. Normoxic cell culture was performed in a standard incubator 
containing 5% CO2 and 20% oxygen.  
Isolation of mRNAs and miRNAs 
Total RNA was extracted using TRIzol (Thermo Fisher Scientific) and used to synthesize 
cDNA with a QuantiTect Reverse Transcription Kit (QIAGEN). Small RNA of CDCs and 
CDCex was isolated using a mirVana PARIS kit (Life Technologies Co.) according to the 
manufacturer’s protocol. Four hundred μl of disruption buffer was added to the cells or 
exosomes, and lysed with an equal volume of denaturing solution. After an acid phenol 
chloroform extraction, the sample tube was centrifuged at 20,000 rpm for 10 min at 4°C. The 
aqueous phase was carefully transferred, mixed with 100% ethanol, and passed two times 
through a mirVana PARIS filter cartridge. Small RNA was eluted in 100 μl of preheated elution 
solution. 
Real-time RT-PCR  
mRNA expression was analyzed by real-time reverse transcription polymerase chain reaction 
(RT-PCR) with pig / human b2-microglobulin (B2M) or human-specific b-actin (ACTB) 
primers and probes (table S4) using Taqman Universal PCR Master Mix (Applied Biosystems), 
as described previously (5). Taqman MicroRNA assays were performed using a TaqMan 
MicroRNA RT kit (Thermo Fisher Scientific) with small RNA primers (table S4) according to 
manufacturer’s protocol. Let-7a and U6 were used as invariant controls for pig and human 
studies, respectively. 




Cardiac functions for trial participants were analyzed using Doppler echocardiogram (EPIQ 7G; 
Philips Healthcare) and cMRI (Siemens 1.5 Tesla MAGNETOM Aera; Siemens AG) with 
single-breath-hold modified Look-Locker inversion recovery sequence and the dichotomous 
variables for presence or absence of LGE were determined quantitatively, as described 
previously (6, 7). The native T1 values were determined by manual tracing of the compacted 
myocardial layers located in the regions with or without prominent trabeculations in every 
single segment of 3 short-axis imaging planes of mid-ventricle using 16-segmental analysis 
(49).  
Growth factor measurement 
The concentration of bFGF in conditioned medium was measured by using enzyme linked 
immunosolvent assay kit (NBP-69961, Novus Biologicals). Concentrations of VEGF and IGF1 
in culture medium were determined by commercially available enzyme immunoassay (LSI 









Fig. S1. Isolation, expansion, and characterization of swine CDCs.  
(A) Surgically collected right atrial tissues were cut into small pieces and grown as an explant 
culture. Harvested explants were reseeded onto poly-D-lysine-coated plates to generate self-
assembly of cardiospheres. CDCs were obtained by reseeding and expanding the cardiospheres 
in adherent culture. (B and C) Immunofluorescence and FACS analysis of swine CDCs for 
expression of CD90, CD105, CD31, and CD45. (D) Cardiac progenitor potential verified by 
mRNA expression of cardiac transcription factors, myocardial structural genes, and growth 
factors by real-time RT-PCR. A pig b2-microgloblin was used as a housekeeping gene. Swine 
heart tissue was used as control. All experiments were repeated more than three times with 






Fig. S2. Cardiac enzyme measurements during occlusive or nonocclusive delivery of CDCs 
in pigs.  
Two weeks after microembolization, a swine model of DCM was randomly subjected to 
treatment with intracoronary infusion of 0.9×107 CDCs suspended in 15 mL with or without a 
stop-flow procedure. Serum cardiac troponin-T (A) and troponin-I (B) were measured before 
and 1 day after delivery. The same amount of intracoronary PBS injection was set as placebo 
control independent of randomization for reference. Dashed lines represent the upper normal 










(A) Randomized preclinical study in a swine model of DCM. DCM pigs were randomly 
assigned to receive placebo, 0.9×107 CDCs, or 1.8×107 CDC infusion. CDCs were delivered 
into three coronary arteries by nonocclusive infusion, and their therapeutic effects were 
compared with placebo injection. Cardiac function was assessed by ultrasound echocardiogram 
(UCG, top) and cMRI (bottom). Absolute changes in LVEF from baseline to 1 month after 
treatment as indicated are shown. (B and C) Myocardial fibrosis was analyzed at 1 month post 
treatment by late gadolinium enhancement (LGE) and Picrosirius red staining. Heart sections 
were stained with myosin heavy chain (MyHC) and von Willebrand factor (vWF, D), Ki67 (E), 
or phospho-histone-H3 (PHH3, F) to evaluate neovascularization and cardiomyocyte 
proliferation. Green arrows show Ki67 or PHH3 positive cardiomyocyte. MyHC negative non-
cardiomyocytes expressing either Ki67 or PHH3 were shown by blue arrows. Scale bar, 10 mm 
in (B) and (C); 50 μm in (D); and 200 μm in (E and F). Statistical significance was determined 







Fig. S4. Effects of GW4869 and HIF-1 inhibitor on exosome release and growth factors 
secretion to modulate adaptive responses to hypoxia. 
(A) Swine CDCs were pretreated with DMSO, GW4869, or acriflavine (ACF, HIF-1 inhibitor) 
for 12 hours and cultured for additional 1 hour under normoxic or hypoxic conditions; HIF-1A 
transcriptional expression was analyzed. CDCs treated with TNF-a (100 ng/mL) for 1 hour 
were shown as a positive control. (B) CDCex release assessed by nanoparticle tracking analysis 
in either normoxic or hypoxic conditioning for 12 hours in CDCs pretreated with DMSO, 
GW4869, or ACF. Proangiogenic growth factor, VEGF (C) and IGF1 (D) and bFGF (E) 
secretion from CDCs with DMSO, GW4869, or ACF treatment in either oxygen condition for 
12 hours. A pig b2-microgloblin was used as a housekeeping gene. Statistical significance was 






Fig. S5. Hypoxic CDCs enhanced secretory miRNA expression that was repressed by 
GW4869 and ACF treatment. 
Swine CDCs pretreated with DMSO, GW4869, or ACF were cultured for 12 hours as indicated 
oxygen conditions. The regulatory effects of GW4869 and ACF on CDCex-derived miRNAs 
were analyzed by real-time RT-PCR (n=5). Let-7a was used as an internal control. Statistical 







Fig. S6. Isolation, expansion, and validation of human CDCs from endomyocardial biopsy 
specimens.  
(A) Endomyocardial biopsy specimens from right ventricle were stained with H&E staining to 
establish a diagnosis. Fibrous infiltration and replacement of the myocardium are shown. 
Human CDCs were isolated from cardiospheres obtained by explant outgrowth and re-plated on 
adherent conditions for expansion to yield a prespecified dose of CDCs. (B and C) Quality 
control validation of CDCs by immunofluorescence and FACS analysis. (D) Cardiac 
transcription factors were examined by real-time RT-PCR. Human cardiac fibroblasts (HCFs) 
were used for comparison. Human-specific b-actin was used as an internal control. Scale bar, 





Fig. S7. Cardiac enzymes and tumor markers measurements for safety profile analysis 
(primary endpoint measures). 
Serum creatine kinases (A and B) and serum cardiac troponin-T and -I (C and D) were 
examined at baseline, 1 day, and 6 months after CDC infusion. Individual participant data are 
shown. (E and F) Tumor marker measurements during 12 months of follow-up. Dashed lines 
represent the upper normal limits. Statistical significance was determined using one-way 







Fig. S8. The impact of miR-146a-5p on TNF-a-mediated autocrine and paracrine 
signaling against apoptosis in human cardiomyocytes.   
(A) Correlations between the CDCex-miR-451a expression relative to U6 (-ΔCT) and changes 




participants at 12 months compared with baseline. (B) miR-146a-5p expression in human AC16 
cardiomyocytes treated with TNF-a (100 ng/mL). (C and D) Verification of miR-146a-5p 
overexpression and antagonizing efficiency by transduction of either mimic, antagomir, or 
respective transfection control against miR-146a-5p in AC16 cardiac cells. Cells without 
transfection were used as controls. (E) TNF-a (200 ng/mL) was administered into AC16 cells 
for 48 hours to induce myocardial apoptosis. The cardioprotective effect conferred by miR-
146a-5p overexpression was shown by FACS. (F) IL6, TRAF6, SMAD4, and FOS expression in 
the presence or absence of TNF-a (100 ng/mL) in culture for 24 hours (n=5) with or without 
antagomir to miR-146a-5p. Human b2-microgloblin was used as internal control. Data were 
analyzed using linear regression analysis using Pearson’s correlation coefficient or one-way 














Procedural death 0 0 0 (0%)  
ST-T change 0 0 5 (100%) 0.008 
VPC 0 0 4 (80%) 0.048 
NSVT 0 0 1 (20%) 1.0 
BP↓ >20 mmHg 0 0 1 (20%) 1.0 
VPC, ventricular premature contraction; NSVT, non-sustained ventricular tachycardia; BP, 
blood pressure. Statistical analysis was performed by Fisher exact test between the groups 
treated by CDCs with or without stop-flow procedure. Placebo controls without randomization 









1. Patients diagnosed as dilated cardiomyopathy. 
2. Patients aged under 18 years old at the time of enrollment.  
3. Left ventricular ejection fraction <40%. 
Exclusion criteria  
1. Contradiction to cardiac magnetic resonance imaging. 
2. Cardiogenic shock. 
3. A patient dependent on extracorporeal circulation. 
4. A patient with lethal or uncontrollable arrhythmia. 
5. A patient with coronary artery disease. 
6. A patient with brain dysfunction due to circulatory failure. 
7. A patient with malignant neoplasm. 
8. A patient with serious neurologic disorder. 
9. A patient with advanced respiratory failure or pulmonary hypertension. 
10. A patient with advanced renal failure. 
11. A patient with multiple organ failure. 
12. Active infection. 
13. Sepsis. 




Table S3. Characteristics of study participants in the TICAP-DCM phase 1a trial. 
 
Patients (n=5) 
Male sex, n 2 (40%) 
Age, y 11.4±6.7 
Body weight, kg 35.8±19.2 
Heart rate, beats/min 98.0±17.0 
Systolic blood pressure, mmHg 100.0±7.3 
Diastolic blood pressure, mmHg 53.0±6.9 
Ross classification 2.4±1.1 
NYUPHFI 11.4±6.9 
BNP, pg/ml 205.2±350.2 
Family history of DCM 0 (0%) 
LBBB 0 (0%) 
Medication  
Diuretics (%) 4 (80%) 
Beta-blocker (%) 5 (100%) 
ACEI or ARB (%) 3 (60%) 
PDE3 inhibitor (%) 2 (40%) 
Dobutamine (%) 2 (40%) 
Aspirin (%) 1 (20%) 
Warfarin (%) 0 (0%) 
Heparin (%) 2 (40%) 
NYUPHFI, New York University pediatric heart failure index; BNP, B-type natriuretic peptide; 
LBBB, left bundle branch block; ACEI, angiotensin converting enzyme inhibitor; ARB, 




Table S4. Taqman primers used for CDC and CDCex validation and function. 
mRNA primers miRNA primers 
Pig ID Pig and human ID 
GATA4 Ss03383805_u1 hsa-miR-126* 000451 
TNNI3 Ss03385977_u1 hsa-miR-132 000457 
IGF1 Ss03394499_m1 hsa-miR-146a 000468 
VEGFA Ss03393991_m1 hsa-miR-210 000512 
HIF1A Ss03390447_m1 hsa-miR-451 001141 
B2M Ss03391156_m1 Pig ID 
Human ID ssc-let-7a 000377 
GATA4 Hs00171403_m1 ssc-miR-181b 245498_mat 
MEF2C Hs00231149_m1 Human ID 
TBX5 Hs00361155_m1 U6 snRNA 001973 
ELASTIN Hs00355783_m1 hsa-miR-181b 001098 
ACTB Hs01060665_g1   
IL6 Hs00174131_m1   
TRAF6 Hs00939742_g1   
SMAD4 Hs00929647_m1   
FOS Hs04194186_s1   
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